Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial

A. Ascierto, Paolo; J. Lipson, Evan; Dummer, Reinhard; Larkin, James; V. Long, Georgina; E. Sanborn, Rachel; Chiarion‐Sileni, Vanna; Dréno, Brigitte; Dalle, Stéphane; Schadendorf, Dirk; K. Callahan, Margaret; Nyakas, Marta; Atkinson, Victoria; Gomez‐Roca, Carlos; Yamazaki, Naoya; A. Tawbi, Hussein; Sarkis, Naomey; Warad, Deepti; Dolfi, Sonia; Mitra, Priyam; Suryawanshi, Satyendra; Grob, Jean‐Jacques

doi:10.1200/jco.22.02072

Public

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial

Published in Journal of Clinical Oncology • Feb 13, 2023

Authors:

Paolo A. Ascierto

Evan J. Lipson

Reinhard Dummer

Abstract

PURPOSE: Nivolumab and relatlimab activity in advanced melanoma with prior progression on anti-programmed death-1/programmed death ligand 1 (PD-(L)1)-containing regimens is under investigation. RELATIVITY-047 demonstrated significantly improved progression-free survival (PFS) for nivolumab and relat...

Subject

Medicine

Nivolumab

Oncology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!